ONC
NASDAQBeOne Medicines Ltd.
Price$312.33+4.81 (+1.56%)
01:30 PM07:45 PM
News · 26 weeks88-61%
2026-01-182026-07-12
Mix7090d
- Insider41(59%)
- SEC Filings15(21%)
- Other12(17%)
- Earnings1(1%)
- Analyst1(1%)
Latest news
25 items- INSIDERChief Executive Officer Oyler John sold $20,163,907 worth of American Depositary Shares (64,628 units at $312.00) as part of a pre-agreed trading plan and exercised 64,628 units of American Depositary Shares at a strike of $119.96 (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERChief Executive Officer Oyler John exercised 283,154 units of American Depositary Shares at a strike of $145.28 and sold $89,351,598 worth of American Depositary Shares (283,154 units at $315.56) as part of a pre-agreed trading plan (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- PRBeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global
- INSIDERChief Executive Officer Oyler John sold $44,626,424 worth of American Depositary Shares (145,861 units at $305.95) as part of a pre-agreed trading plan and exercised 133,600 units of American Depositary Shares at a strike of $54.06, closing all direct ownership in the company (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERChief Executive Officer Oyler John exercised 60,218 units of American Depositary Shares at a strike of $36.90 and sold $18,256,808 worth of American Depositary Shares (60,218 units at $303.18) as part of a pre-agreed trading plan (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- SECSEC Form 144 filed by BeOne Medicines Ltd.144 - BeOne Medicines Ltd. (0001651308) (Subject)
- ANALYSTBeOne Medicines upgraded by Jefferies with a new price targetJefferies upgraded BeOne Medicines from Hold to Buy and set a new price target of $380.00
- INSIDERSVP, General Counsel Lee Chan Henry sold $200,833 worth of American Depositary Shares (664 units at $302.46) as part of a pre-agreed trading plan and exercised 664 units of American Depositary Shares at a strike of $191.56 (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- SECSEC Form 144 filed by BeOne Medicines Ltd.144 - BeOne Medicines Ltd. (0001651308) (Subject)
- SECSEC Form 144 filed by BeOne Medicines Ltd.144 - BeOne Medicines Ltd. (0001651308) (Subject)
- PRBeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell LymphomaFoundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), meeting the primary endpoint of PFS MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026 BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-30
- SECBeOne Medicines Ltd. filed SEC Form 8-K: Other Events8-K - BeOne Medicines Ltd. (0001651308) (Filer)
- INSIDERPresident and COO Wu Xiaobin sold $356,927 worth of American Depositary Shares (1,292 units at $276.26), closing all direct ownership in the company (SEC Form 4) to cover withholding tax4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERChief Executive Officer Oyler John sold $933,592 worth of American Depositary Shares (3,410 units at $273.78), closing all direct ownership in the company (SEC Form 4) to satisfy withholding obligation4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERPresident, Global Head of R&D Wang Lai sold $295,553 worth of American Depositary Shares (1,068 units at $276.74), closing all direct ownership in the company (SEC Form 4) (withholding tax)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- SECSEC Form 144 filed by BeOne Medicines Ltd.144 - BeOne Medicines Ltd. (0001651308) (Subject)
- INSIDERPresident and COO Wu Xiaobin sold $361,997 worth of American Depositary Shares (1,357 units at $266.76), closing all direct ownership in the company (SEC Form 4) to cover taxes4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERSVP, General Counsel Lee Chan Henry sold $156,925 worth of American Depositary Shares (590 units at $265.98), closing all direct ownership in the company (SEC Form 4) to cover taxes4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERChief Executive Officer Oyler John sold $980,686 worth of American Depositary Shares (3,693 units at $265.55), closing all direct ownership in the company (SEC Form 4) to satisfy tax liability4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERPresident, Global Head of R&D Wang Lai sold $310,236 worth of American Depositary Shares (1,169 units at $265.39), closing all direct ownership in the company (SEC Form 4) (tax liability)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- SECSEC Form 144 filed by BeOne Medicines Ltd.144 - BeOne Medicines Ltd. (0001651308) (Subject)
- INSIDERPrincipal Accounting Officer Ball Titus B. was granted 31,213 units of Ordinary Shares and sold $43,467 worth of American Depositary Shares (169 units at $257.20), closing all direct ownership in the company (SEC Form 4) (for tax liability)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERPresident, Global Head of R&D Wang Lai was granted 118,625 units of Ordinary Shares and sold $197,318 worth of American Depositary Shares (756 units at $261.00), closing all direct ownership in the company (SEC Form 4) (tax liability)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERChief Financial Officer Rosenberg Aaron was granted 71,175 units of Ordinary Shares and sold $162,637 worth of American Depositary Shares (631 units at $257.74), closing all direct ownership in the company (SEC Form 4) (for withholding tax)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERSVP, General Counsel Lee Chan Henry was granted 45,071 units of Ordinary Shares and sold $110,268 worth of American Depositary Shares (428 units at $257.63), closing all direct ownership in the company (SEC Form 4) (tax withholding)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
ONC FAQ
6 questionsWhere does ONC stock trade?
BeOne Medicines Ltd. (ONC) is listed on NASDAQ.What sector and industry is ONC in?
BeOne Medicines Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did BeOne Medicines Ltd. go public?
BeOne Medicines Ltd. (ONC) completed its IPO in 2016.What are analysts saying about ONC?
BeOne Medicines Ltd. has had 7 recent analyst actions on file. The most recent action was from Jefferies: Buy on 2026-07-13.What companies are similar to ONC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ONC side-by-side with any of them on Quantisnow.How can I track ONC on Quantisnow?
Quantisnow aggregates BeOne Medicines Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ONC to receive live email and push alerts on every new disclosure.